---
id: endolysin-therapy_253
category: antimicrobials
tags: [endolysin, phage-therapy, antimicrobial-peptides, gram-negative]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Endolysin Therapy: Mechanism and Engineering Strategies

**Q:** How do endolysins differ from intact bacteriophages, and what strategies overcome the Gram-negative outer membrane barrier? (Use mnemonic **LEAP**)

**A:**

**Endolysin Advantages:**
- Peptidoglycan hydrolases that **directly lyse bacteria** (no replication needed)
- **Low resistance potential** (target conserved cell wall; no efflux pump escape)
- No toxicity to human/animal cells
- **Immediate bactericidal** action

**Gram-Negative Challenge:** Outer membrane blocks endolysin access to periplasmic peptidoglycan

**LEAP Engineering Strategies:**
- **L**iposome/nanoparticle encapsulation
- **E**DTA/citric acid permeabilizers
- **A**MP-endolysin fusion proteins (C-terminal fusion preferred)
- **P**rotein engineering (mutagenesis, domain shuffling)

**Clinical Development:**
- **CF-301 (Exebacase)**: FDA Breakthrough Therapy (2020), Phase III for *S. aureus* bacteremia
- **RAP-29**: Cryptic AMP from PhiKo endolysin (broad-spectrum)
- **Synergy**: Endolysin + LL-37 effective against VRE; endolysin + colistin synergistic for MDR Gram-negatives

**Media:**

**Sources:** [PMC11144922 - Endolysins vs Gram-Negatives], [PMC12170589 - AMP-Endolysin Fusions 2024], [WHO Novel Antimicrobials List]
